Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/critical-issues-in-head-and-neck-oncology/descriptif_3838977
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3838977

Critical Issues in Head and Neck Oncology, 1st ed. 2018 Key Concepts from the Sixth THNO Meeting

Langue : Anglais

Coordonnateurs : Vermorken Jan B., Budach Volker, Leemans C. René, Machiels Jean-Pascal, Nicolai Piero, O'Sullivan Brian

Couverture de l’ouvrage Critical Issues in Head and Neck Oncology

This book provides an overview of the latest advances in head and neck cancer using a multidisciplinary approach. Commencing with a discussion of epidemiological and diagnostic aspects, including the role of vaccination and key pathological features, the book then follows by examining the role of oncogenomics, proteomics, next generation sequencing and homologous recombination function in predicting outcomes. The topics are presented by epidemiologists, pathologists and basic scientists with further contributions from medical oncologists, head and neck cancer surgical specialists (ORL /HNS), and radiation oncologists in chapters that discuss therapeutic approaches for oral, oropharyngeal and thyroid cancer. Special topics such as the development of novel staging classifications, optimal larynx preservation approaches for laryngeal and hypopharyngeal cancer, surgical reconstruction, new surgical approaches in oropharynx cancer, potential for treatment de-escalation, systemic therapyin nasopharyngeal cancer and salivary gland tumors and treatment approaches for tumors of unknown primary site are discussed in detail. Finally, the role of immunotherapy in the field is highlighted.

The chapters are based on the latest data presented at the 6th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field. They are written by many of the most internationally acclaimed authors in the field and are therefore an excellent source for all those interested or actively working in the field of head and neck cancer.


Part I.    Epidemiology and diagnosis.- The role of vaccination in head and neck cancer prevention.- Cellular and molecular pathology in head and neck cancer.- Part II.         Prediction of outcome.- Oncogenomics/proteomics of head and neck cancer.- Targeted next-generation sequencing in head and neck cancer.- Homologous recombination function as predictor of treatment response.- Part III.  Oral cavity cancer.- Surgical management of oral cavity cancer.- Reconstruction in oral cavity cancer: when and how.- Induction chemotherapy: does it have a place in oral cavity cancer?.- Are there alternative local treatments in oral cavity cancer?.- Part IV.  Oropharynx cancer.- HPV assessment in oropharynx cancer: what is the gold standard?.- A new staging system for oropharynx cancer and why?.- Should we de-escalate the treatment in HPV-positive oropharynx cancer?.- Is there a new role for surgery in oropharynx cancer?.- Can we expect less toxicity with newer forms of radiation?.- Part V.  Miscellaneous topics.- What is the optimal larynx preservation approach and who are the candidates?.- Is the approach to patients with unknown primary tumors any different in 2017?.- Cytotoxic chemotherapy and targeted therapy in nasopharynx cancer.- Are there alternative chemotherapy regimens for EXTREME in recurrent/metastatic SCCHN.- New data on systemic therapy of salivary gland tumors.- Treatment of elderly patients with head and neck cancer.- Part VI.  Thyroid cancer.- World-wide thyroid cancer epidemics: what is going on?.- The surgical approach to thyroid cancer in 2017.- Part VII. Keynote address.- Immunology and immunotherapy in head and neck cancer.- 

Prof. Jan B. Vermorken started his medical training in 1961, graduated in 1970 from the University of Amsterdam, the Netherlands, and became a board-certified specialist in internal medicine in 1975. Since that time he has worked in the field of Medical Oncology and was officially registered as a Medical Oncologist in the Netherlands in 1992. He received his PhD in Medical Sciences in 1986 from the Vrije Universiteit in Amsterdam.  From May 1997 until October 1, 2009, he was appointed Professor of Oncology at the University of Antwerp (UA), and head of the Department of Medical Oncology at the University Hospital Antwerp (UZA), in Edegem, Belgium. After his retirement he remains connected to both University (Emeritus Professor) and University Hospital (consultant).

His main fields of interest are head and neck oncology and gynecologic oncology. He chaired both the Head and Neck Cancer Group (2006-2009) and the Gynecologic Cancer Group (1983-1989) of the European Organization for the Research and Treatment of cancer (EORTC). He was founding chair of the Gynecologic Cancer InterGroup (GCIG: 1997-2003) and strongly involved in establishing the Head and Neck Cancer International Group (HNCIG) in 2015.   He devotes a large part of his time to teaching, professional training, and continuing medical education.

Professor Vermorken is member of various scientific societies, member of several editorial boards of International journals, reviewer of multiple cancer journals and author or co-author of 700 publications. He was Editor-in-Chief of Annals of Oncology from 2009 to 2014 and is chief editor of the head and neck cancer section of The Oncologist (since 2003), and the head and neck section of Frontiers in Oncology (since 2015), is editorial chair of ONCOhemato (multidisciplinary journal; since 2007) in Belgium and chairs Oncotherapie (an internet platform) in The Netherlands (since 2007) . He received the ESMO award in 2007 and on

Provides a multidisciplinary perspective to head and neck cancer management Uses an evidence-based approach based on the latest developments in the field Written by world-class experts in head and neck oncology

Date de parution :

Ouvrage de 363 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

137,14 €

Ajouter au panier